Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).

Karen L. Reckamp; Philip C. Mack; Nora Ruel; Paul Henry Frankel; Barbara J. Gitlitz; Tianhong Li; Marianna Koczywas; Shirish M. Gadgeel; Mihaela C. Cristea; Chandra Prakash Belani; Edward M. Newman; David R. Gandara; Primo Lara

doi:10.1200/jco.2015.33.15_suppl.8087

Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8087 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8087-8087 ◽

Cited By ~ 6

Author(s):

Karen L. Reckamp ◽

Philip C. Mack ◽

Nora Ruel ◽

Paul Henry Frankel ◽

Barbara J. Gitlitz ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Biomarker Analysis ◽

Tki Resistance ◽

Epidermal Growth ◽

Egfr Mutant

Download Full-text

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Frontiers in Oncology ◽

10.3389/fonc.2019.00132 ◽

2019 ◽

Vol 9 ◽

Cited By ~ 10

Author(s):

Karen L. Reckamp ◽

Paul H. Frankel ◽

Nora Ruel ◽

Philip C. Mack ◽

Barbara J. Gitlitz ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Tyrosine Kinase Inhibitor Therapy ◽

Epidermal Growth ◽

Egfr Mutant

Download Full-text

Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8014 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8014-8014 ◽

Cited By ~ 14

Author(s):

Karen L. Reckamp ◽

Paul Henry Frankel ◽

Philip C Mack ◽

Barbara Jennifer Gitlitz ◽

Nora Ruel ◽

...

Keyword(s):

Phase Ii ◽

Progressive Disease ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Epidermal Growth ◽

Egfr Mutant

Download Full-text

Clinical Significance of Sequential Treatment with Afatinib in the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Treatment of Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3935 ◽

2019 ◽

Author(s):

N. Kobayashi ◽

H. Aiko ◽

C. Kamimaki ◽

N. Mikami ◽

S. Kubo ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Epidermal Growth ◽

Tki Treatment ◽

Egfr Mutant

Download Full-text

Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyz023 ◽

2019 ◽

Vol 49 (6) ◽

pp. 554-558 ◽

Cited By ~ 5

Author(s):

Kazuhiro Usui ◽

Takuma Yokoyama ◽

Go Naka ◽

Hiroo Ishida ◽

Kazuma Kishi ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Epidermal Growth ◽

Egfr Mutant ◽

Inhibitor Treatment

Download Full-text

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor

Cancer Management and Research ◽

10.2147/cmar.s326349 ◽

2021 ◽

Vol Volume 13 ◽

pp. 7517-7526

Author(s):

Yalin Xie ◽

Ning Su ◽

Wei Zhou ◽

An Lei ◽

Xiang Li ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Pulmonary Tuberculosis ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Epidermal Growth ◽

Egfr Mutant

Download Full-text

First‐line epidermal growth factor receptor ( EGFR )–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR ‐mutated lung adenocarcinoma

Cancer Science ◽

10.1111/cas.13079 ◽

2016 ◽

Vol 107 (12) ◽

pp. 1800-1805 ◽

Cited By ~ 24

Author(s):

Yongshun Chen ◽

Jing Yang ◽

Xue Li ◽

Daxuan Hao ◽

Xiaoyuan Wu ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Whole Brain Radiotherapy ◽

First Line ◽

Egfr Tyrosine Kinase Inhibitor ◽

Brain Radiotherapy ◽

Epidermal Growth ◽

Egfr Mutated

Download Full-text

A phase II trial of ZD1839 (Iressa?) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

Investigational New Drugs ◽

10.1007/s10637-005-5862-9 ◽

2005 ◽

Vol 23 (2) ◽

pp. 165-170 ◽

Cited By ~ 45

Author(s):

Mary J. MacKenzie ◽

Holger W. Hirte ◽

Goss Glenwood ◽

Maroun Jean ◽

Rakesh Goel ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Epidermal Growth

Download Full-text

Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/0360-3016(92)91009-c ◽

1992 ◽

Vol 22 (1) ◽

pp. 225-230 ◽

Cited By ~ 96

Author(s):

Luther W. Brady ◽

Curtis Miyamoto ◽

David V. Woo ◽

Michael Rackover ◽

Jacqueline Emrich ◽

...

Keyword(s):

Monoclonal Antibody ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Malignant Astrocytomas ◽

Epidermal Growth ◽

Iodine 125

Download Full-text

Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.2001 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 2001-2001 ◽

Cited By ~ 5

Author(s):

M. Dickler ◽

H. Rugo ◽

J. Caravelli ◽

E. Brogi ◽

D. Sachs ◽

...

Keyword(s):

Growth Factor ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Vascular Endothelial ◽

Egfr Tyrosine Kinase Inhibitor ◽

Humanized Monoclonal Antibody ◽

Epidermal Growth ◽

Endothelial Growth Factor

Download Full-text

A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3162 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3162-3162 ◽

Cited By ~ 3

Author(s):

I. B. Vergote ◽

Y. Humblet ◽

E. van Cutsem ◽

S. van Belle ◽

J. Kerger ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Solid Tumors ◽

Phase Ii ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Multicenter Phase ◽

Epidermal Growth

Download Full-text